LDL

LDL製品

All (6)
LDL抗体(1)
LDLモジュレータ(5)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1655	Ezetimibe (SCH-58235)	Ezetimibe (SCH-58235) is a potent, selective, cholesterol absorption inhibitor, used to lower cholesterol.	J Immunother Cancer, 2024, 12(11)e009805 EMBO Mol Med, 2022, 14(2):e14903 Exp Hematol Oncol, 2022, 11(1):51
S2748	Anacetrapib (MK-0859)	Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3.	Circulation, 2021, 143(9):921-934 J Phys Chem B, 2016, 120(33):8254-63 Atherosclerosis, 2014, 235(2):449-62
S7953	Bempedoic acid (ETC-1002)	Bempedoic acid (ETC-1002), also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an activator of hepatic AMP-activated protein kinase (AMPK). It has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).	iScience, 2023, 26(12):108532 Oncol Rep, 2023, 49(2)32 Biomed Pharmacother, 2021, 144:112325
S2119	Probucol	Probucol (DH-581) is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.	J Immunother Cancer, 2024, 12(11)e009805 Int Immunopharmacol, 2023, 116:109820
A2386	Orticumab (Anti-oxLDL)	Orticumab (MLDL1278A) is an antibody targeting oxidized or malondialdehyde-modified lipoprotein (LDL) that specifically inhibits oxidised low-density lipoproteins (oxLDL). Orticumab is involved in the modulation of autoimmune responses against oxLDL and improves atherosclerosis in an animal model. MW: 145.5 kD.
S9187	Phillygenin	Phillygenin (Sylvatesmin), a bioactive intergradient in Osmanthus fragrans, has anti-inflammatory, anti-obesity and antipyretic activities. It could reduce blood lipid levels and low density lipoprotein.
A2386	Orticumab (Anti-oxLDL)	Orticumab (MLDL1278A) is an antibody targeting oxidized or malondialdehyde-modified lipoprotein (LDL) that specifically inhibits oxidised low-density lipoproteins (oxLDL). Orticumab is involved in the modulation of autoimmune responses against oxLDL and improves atherosclerosis in an animal model. MW: 145.5 kD.
S1655	Ezetimibe (SCH-58235)	Ezetimibe (SCH-58235) is a potent, selective, cholesterol absorption inhibitor, used to lower cholesterol.	J Immunother Cancer, 2024, 12(11)e009805 EMBO Mol Med, 2022, 14(2):e14903 Exp Hematol Oncol, 2022, 11(1):51
S2748	Anacetrapib (MK-0859)	Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3.	Circulation, 2021, 143(9):921-934 J Phys Chem B, 2016, 120(33):8254-63 Atherosclerosis, 2014, 235(2):449-62
S7953	Bempedoic acid (ETC-1002)	Bempedoic acid (ETC-1002), also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an activator of hepatic AMP-activated protein kinase (AMPK). It has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).	iScience, 2023, 26(12):108532 Oncol Rep, 2023, 49(2)32 Biomed Pharmacother, 2021, 144:112325
S2119	Probucol	Probucol (DH-581) is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.	J Immunother Cancer, 2024, 12(11)e009805 Int Immunopharmacol, 2023, 116:109820
S9187	Phillygenin	Phillygenin (Sylvatesmin), a bioactive intergradient in Osmanthus fragrans, has anti-inflammatory, anti-obesity and antipyretic activities. It could reduce blood lipid levels and low density lipoprotein.

LDL阻害剤の選択性比較

Tags: LDL modulation | LDL modulator | LDL regulation| LDL review